{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:57Z","timestamp":1792791537087,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.10.003","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:56:24Z","timestamp":1792720584000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-7650","authenticated-orcid":false,"given":"Kevin","family":"Shee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"Cornelia Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan L.","family":"Raizenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry P.","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Stohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Sirohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa E.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Chappidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao G.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.10.003_b0005","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jnci\/djac066","article-title":"Grade migration of prostate cancer in the United States during the last decade","volume":"114","author":"Borregales","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2026.10.003_b0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/JU.0000000000002354","article-title":"Evaluating the outcomes of active surveillance in grade Group 2 prostate cancer: prospective results from the Canary PASS cohort","volume":"207","author":"Waisman Malaret","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.29760","article-title":"Trends in active surveillance for men with intermediate-risk prostate cancer","volume":"7","author":"Diven","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.10.003_b0020","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.10.003_b0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.10.003_b0030","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2010.31.4252","article-title":"Outcomes of active surveillance for men with intermediate-risk prostate cancer","volume":"29","author":"Cooperberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2026.10.003_b0045","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0050","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JU.0000000000000742","article-title":"Risk of metastasis in men with grade Group 2 prostate cancer managed with active surveillance at a tertiary cancer center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0055","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JU.0000000000001313","article-title":"The long-term risks of metastases in men on active surveillance for early stage prostate cancer","volume":"204","author":"Maggi","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.euo.2018.04.018","article-title":"Effects of initial Gleason grade on outcomes during active surveillance for prostate cancer","volume":"1","author":"Masic","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0065","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bju.16666","article-title":"The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer","volume":"135","author":"Gnanapragasam","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.10.003_b0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euo.2023.11.011","article-title":"The impact of delayed radical prostatectomy on recurrence outcomes after initial active surveillance: results from a large institutional cohort","volume":"7","author":"Shee","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0075","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(25)00438-3","article-title":"Revisiting prostate cancer active surveillance candidacy","volume":"26","author":"Spratt","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0080","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/JU.0000000000001089","article-title":"Delayed radical prostatectomy is not associated with adverse oncologic outcomes: implications for men experiencing surgical delay due to the COVID-19 pandemic","volume":"204","author":"Ginsburg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2013.01.019","article-title":"Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance","volume":"190","author":"Satkunasivam","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0090","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.juro.2018.09.042","article-title":"Defining intermediate risk prostate cancer suitable for active surveillance","volume":"201","author":"Loeb","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JU.0000000000003461","article-title":"Identifying men who can remain on active surveillance despite biopsy reclassification to grade Group 2 prostate cancer","volume":"210","author":"Baraban","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0100","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/JU.0000000000002885","article-title":"Final analysis of the magnetic resonance imaging in active surveillance trial","volume":"208","author":"Doan","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0105","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.juro.2016.09.070","article-title":"Targeted biopsy to detect Gleason score upgrading during active surveillance for men with low versus intermediate risk prostate cancer","volume":"197","author":"Nassiri","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.urology.2017.07.071","article-title":"Prostate-specific antigen density is a good predictor of upstaging and upgrading, according to the new grading system: the keys we are seeking may be already in our pocket","volume":"111","author":"Brassetti","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.10.003_b0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2016.08.043","article-title":"Adverse disease features in Gleason score 3 + 4 \u201cfavorable intermediate-risk\u201d prostate cancer: implications for active surveillance","volume":"72","author":"Morlacco","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.euo.2025.06.012","article-title":"Predicting active surveillance failure for patients with prostate cancer in the magnetic resonance imaging era: a multicentre transatlantic cohort study","volume":"9","author":"Sushentsev","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0125","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/JU.0000000000001519","article-title":"Selecting patients with favorable risk, grade Group 2 prostate cancer for active surveillance-does magnetic resonance imaging have a role?","volume":"205","author":"Stonier","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.eururo.2025.03.019","article-title":"Magnetic resonance imaging-led risk-adapted active surveillance for prostate cancer: updated results from a large cohort study","volume":"88","author":"Englman","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0135","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/JU.0000000000004117","article-title":"Association of baseline magnetic resonance imaging prostate imaging reporting and data system score with prostate cancer active surveillance early biopsy reclassification: data from the Michigan urological surgery improvement collaborative (MUSIC)","volume":"212","author":"Nandalur","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.10.003_b0140","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.euo.2025.06.005","article-title":"The natural history of confirmed grade Group 1 prostate cancer managed with active surveillance in the modern era","volume":"8","author":"Shee","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","article-title":"Validation of the Decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance","volume":"22","author":"Kim","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.10.003_b0150","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bju.13911","article-title":"Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance","volume":"120","author":"Tosoian","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.10.003_b0155","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.19.02267","article-title":"17-gene genomic prostate score test results in the canary prostate active surveillance study (PASS) cohort","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.10.003_b0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euros.2022.01.008","article-title":"Association between a 22-feature genomic classifier and biopsy Gleason upgrade during active surveillance for prostate cancer","volume":"37","author":"Press","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.10.003_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euf.2025.04.027","article-title":"Gleason grade Group 3 represents a spectrum of disease: results from a large institutional cohort","volume":"12","author":"Shee","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.10.003_b0170","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/his.15231","article-title":"Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage","volume":"85","author":"Nguyen","year":"2024","journal-title":"Histopathology"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:39Z","timestamp":1792788759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S2588931126002853"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.10.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}